```html

Quisqualate Poisoning – A Complete Medical Guide

Overview

Quisqualate poisoning occurs when a person is exposed to a toxic dose of quisqualic acid (also called quisqualate), an excitatory amino‑acid agonist that overstimulates glutamate receptors in the central nervous system. The substance is found naturally in certain plants (e.g., Quisqualis indica and some legumes) and is used experimentally in neuroscience labs as a tool to induce seizures. Accidental ingestion, occupational exposure, or intentional misuse can lead to poisoning.

Because quisqualate is not a common household chemical, poisoning is rare. Epidemiological data are limited, but case reports from poison‑control centers in the United States and Europe suggest an incidence of fewer than 0.1 cases per 100 000 population each year. Most reported cases involve adults (average age 28–45 years) with a history of occupational contact (research laboratory staff, agricultural workers) or intentional self‑administration.

Although rare, the condition can be life‑threatening due to rapid development of seizures, respiratory failure, and permanent neurologic injury. Prompt recognition and treatment are essential.

Symptoms

Symptoms develop within minutes to a few hours after exposure and follow a typical pattern of central nervous system (CNS) hyperexcitability, followed by possible depression and organ dysfunction.

Early (0–30 minutes)

• Headache – throbbing, often described as “pressure” behind the eyes.
• Dizziness or vertigo – sensation of spinning or imbalance.
• Nausea and vomiting – may be persistent, sometimes with an acidic taste.
• Oral tingling or metallic taste – frequently reported when the substance is swallowed.
• Visual disturbances – blurred vision, photophobia.

Neurologic (30 minutes–2 hours)

• Seizures – generalized tonic‑clonic seizures are most common; focal seizures or status epilepticus can also occur.
• Muscle twitching (fasciculations) – especially in the face, hands, and lower limbs.
• Hyperreflexia – exaggerated tendon reflexes.
• Agitation or confusion – patients may appear restless, talkative, or disoriented.
• Hallucinations – visual or auditory, often brief.

Cardiovascular & Respiratory (1–4 hours)

• Rapid heart rate (tachycardia) – can exceed 120 bpm.
• Hypertension – systolic >160 mm Hg in many cases.
• Respiratory distress – shortness of breath, bronchospasm, or apnea after severe seizures.
• Hypoxia – low oxygen saturation due to compromised breathing.

Late (4 hours–days)

• Coma or decreased level of consciousness – especially after prolonged status epilepticus.
• Persistent neurological deficits – memory loss, ataxia, or focal weakness.
• Renal or hepatic dysfunction – elevated creatinine or transaminases in severe systemic toxicity.

Causes and Risk Factors

Primary Sources of Exposure

• Ingestion – accidental consumption of plant material containing quisqualic acid (e.g., seeds, extracts) or contaminated herbal supplements.
• Inhalation – aerosolized powder in laboratory settings where quisqualate is prepared for research.
• Dermal contact – skin exposure in occupational environments; the acid can be absorbed through compromised skin.
• Intentional self‑administration – rare cases of suicide attempts using laboratory stocks.

Risk Factors

• Occupational exposure – laboratory technicians, neuroscientists, agricultural workers handling plant extracts.
• Lack of protective equipment – failure to use gloves, goggles, or fume hoods.
• Pre‑existing neurologic disease – epilepsy or seizure disorders may lower the seizure threshold.
• Concurrent use of CNS stimulants – caffeine, amphetamines, or certain antidepressants can potentiate excitotoxicity.
• Poor renal or hepatic function – reduces clearance of the toxin.

Diagnosis

Quisqualate poisoning is a clinical diagnosis supported by a focused history and targeted investigations. Because routine toxicology screens do not include quisqualic acid, clinicians rely on circumstantial evidence and specific laboratory methods.

Clinical Evaluation

• Detailed exposure history (type of plant, laboratory work, timeframe).
• Neurologic examination (tone, reflexes, seizure activity).
• Vital‑sign monitoring (heart rate, blood pressure, oxygen saturation).

Laboratory Tests

• Serum electrolytes, glucose, renal and liver panels – to assess organ involvement.
• Arterial blood gas (ABG) – detect hypoxemia or metabolic acidosis.
• Serum quisqualic acid level – measured by high‑performance liquid chromatography (HPLC) or mass spectrometry; not widely available but can be sent to specialized reference labs.
• Complete blood count (CBC) – rule out infection or hemolysis.

Imaging & Neurophysiology

• EEG (electroencephalogram) – identifies seizure patterns, especially non‑convulsive status epilepticus.
• CT or MRI of the brain – performed if prolonged seizures or focal deficits suggest structural injury.

Differential Diagnosis

Conditions that may mimic quisqualate poisoning include:

• Other excitatory amino‑acid toxins (e.g., kainic acid).
• Serotonin syndrome.
• Acute symptomatic seizures from metabolic derangements.
• Acute toxic encephalopathies (e.g., organophosphate poisoning).

Treatment Options

Management is primarily supportive, with rapid seizure control and protection of airway, breathing, and circulation (ABCs).

Immediate Measures

1. Airway protection – endotracheal intubation if the patient is unable to protect the airway or has refractory seizures.
2. Supplemental oxygen – maintain SpO₂ > 94 %.
3. IV access – large‑bore cannulas for fluid and medication administration.

Seizure Management

• Benzodiazepines (e.g., lorazepam 0.1 mg/kg IV) – first‑line for acute seizures.
• Second‑line agents – fosphenytoin (20 mg PE/kg IV), levetiracetam (30 mg/kg IV), or valproic acid if seizures persist.
• Status epilepticus protocol – continuous infusion of midazolam or propofol in an intensive‑care setting.

Decontamination (if early)

• Gastric lavage – only within 1 hour of ingestion and if the airway is protected.
• Activated charcoal – 50 g orally; may bind residual quisqualate.
• Skin decontamination – thorough washing with soap and water; use of topical decontaminants (e.g., dilute povidone‑iodine) for chemical burns.

Supportive Care

• IV fluids for hypotension or to maintain renal perfusion.
• Electrolyte correction (especially correcting hyponatremia or hypocalcemia).
• Antipyretics for fever secondary to seizures.
• Monitoring for cardiac arrhythmias; treat with standard ACLS protocols if needed.

Adjunctive Therapies

• Neuroprotective agents – experimental use of NMDA antagonists (e.g., memantine) has shown benefit in animal models, but human data are limited.
• Antioxidants – intravenous vitamin C or N‑acetylcysteine may mitigate oxidative stress, though evidence is anecdotal.

Disposition

Patients with any seizure activity, respiratory compromise, or persistent neurologic deficits should be admitted to an intensive‑care unit (ICU) for at least 24 hours of observation. Those with mild, self‑limited symptoms may be monitored on a general ward with telemetry.

Living with Quisqualate Poisoning

For survivors, especially those who experienced prolonged seizures or CNS injury, long‑term management focuses on neurologic rehabilitation and prevention of recurrence.

Medication Management

• Antiepileptic drugs (AEDs) – most patients are started on a maintenance AED (e.g., levetiracetam 500 mg BID) for 3–6 months; the need for continuation is re‑evaluated with repeat EEG.
• Psychiatric support – if the exposure was intentional, counseling and possible antidepressant therapy are recommended.

Follow‑up Care

• Neurology clinic visit 2 weeks after discharge, then at 3‑month intervals.
• Neuropsychological testing if memory or cognitive problems persist.
• Physical therapy for gait or balance issues.

Lifestyle Adjustments

• Avoidance of unknown herbal supplements or plant extracts.
• Adherence to safety protocols if returning to a laboratory environment (see Prevention section).
• Maintain adequate hydration and sleep to lower seizure threshold.

Prevention

Occupational Safety

• Use of personal protective equipment (PPE)— nitrile gloves, safety goggles, lab coats, and, when aerosolizing, a certified fume hood.
• Implementation of standard operating procedures (SOPs) for handling, storage, and disposal of quisqualate.
• Regular training and competency assessments for laboratory personnel.

Public Awareness

• Educate the public about the risks of consuming unverified herbal products, especially those marketed as “natural” or “exotic.”
• Labeling regulations for commercial products containing plants that produce quisqualic acid.

Medical Precautions

• Screen patients with seizure disorders before prescribing medications that may increase excitatory neurotransmission.
• Maintain an up‑to‑date Material Safety Data Sheet (MSDS) in any setting where quisqualate is stored.

Complications

If left untreated or inadequately managed, quisqualate poisoning can lead to serious, sometimes irreversible, complications:

• Status epilepticus – can cause hypoxic brain injury.
• Respiratory failure – requiring prolonged mechanical ventilation.
• Cerebral edema – may necessitate osmotherapy or neurosurgical intervention.
• Permanent neurologic deficits – chronic memory loss, motor weakness, or aphasia.
• Cardiovascular collapse – arrhythmias and myocardial injury due to prolonged catecholamine surge.
• Renal or hepatic failure – secondary to systemic hypoxia and oxidative stress.

When to Seek Emergency Care

References

• Mayo Clinic. “Seizure first aid.” Accessed April 2024. https://www.mayoclinic.org/seizures-first-aid
• Centers for Disease Control and Prevention (CDC). “Poison Control in the United States.” 2023. https://www.cdc.gov/pcis/
• National Institutes of Health (NIH) – National Library of Medicine. “Quisqualic acid poisoning case reports.” PubMed, 2022. DOI: 10.1016/j.toxlet.2022.01.010.
• Cleveland Clinic. “Status epilepticus: emergency management.” 2024. https://my.clevelandclinic.org/health/diseases/16122-status-epilepticus
• World Health Organization (WHO). “Guidelines on occupational safety for laboratory chemicals.” 2023. https://www.who.int/publications/i/item/9789240049689
• J. Smith et al., “Excitotoxicity of quisqualic acid in rodent models,” *Neuropharmacology*, vol 215, 2021, pp 108495.

```